ID   LNCaP-19
AC   CVCL_WW88
SY   LNCaP cells from passage 19
DR   cancercelllines; CVCL_WW88
DR   Wikidata; Q95982755
RX   PubMed=15389782;
CC   Population: Caucasian.
CC   Characteristics: Androgen-independent.
CC   Doubling time: 46 hours (PubMed=15389782); 50.00 hours (GrayJW panel).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1379 ! LNCaP clone FGC
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 05-10-23; Version: 9
//
RX   PubMed=15389782; DOI=10.1002/pros.20145;
RA   Gustavsson H., Welen K., Damber J.-E.;
RT   "Transition of an androgen-dependent human prostate cancer cell line
RT   into an androgen-independent subline is associated with increased
RT   angiogenesis.";
RL   Prostate 62:364-373(2005).
//